AbbVie (NYSE:ABBV) traded higher in the premarket on Friday after setting its 2025 earnings outlook in line with expectations ...

AbbVie (ABBV) stock rallied today after the biopharmaceutical company posted its Q4 2024 earnings report. The good news ...

Welcome to the AbbVie fourth-quarter 2024 Earnings Conference Call. [Operator instructions] Today's call is also being recorded. If you have any objections, you may disconnect at this time. I would ...

AbbVie Q4 earnings beat estimates, driven by strong sales of Skyrizi and Rinvoq, with an updated 2027 combined revenue ...

Shares of AbbVie ( ABBV 6.95%) were jumping 7.1% higher as of 11:10 a.m. ET on Friday after rising as much as 9.2% earlier in ...

He emphasized the consistent outperformance of the ex-Humira platform, which grew over 18% annually and accelerated to 22% growth in Q4. The company projects mid-single-digit revenue growth in 2025, ...

Reports Q4 revenue $15.1B, consensus $14.83B. “2024 was a year of significant progress for AbbVie (ABBV). Our growth platform delivered ...

AbbVie (ABBV) delivered earnings and revenue surprises of 1.41% and 1.56%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion ...

AbbVie (NYSE:ABBV) saw its shares jump more than 4% in premarket trading Friday after the company's profit guidance for the fiscal 2025 year exceeded analyst expectations, driven by strong sales in ...

NORTH CHICAGO, Ill. (AP) — NORTH CHICAGO, Ill. (AP) — AbbVie Inc. (ABBV) on Friday reported a fourth-quarter loss of $22 million, after reporting a profit in the same period a year earlier.

AbbVie and Novartis to report Q4 earnings. AbbVie in stagnating trend, Novartis bullish. Breakdown of technical charts. Novartis has advantage, investors watch for post-earnings movement.